Characterization of ocular adverse events in patients receiving belantamab mafodotin (belamaf) for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory multiple myeloma (RRMM)

被引：0
|
作者：
Trautmann-Grill, K. [1 ]
Lonial, S. [2 ]
Nooka, A. K. [2 ]
Thulasi, P. [3 ]
Badros, A. Z. [4 ]
Jeng, B. H. [4 ]
Callander, N. S. [5 ]
Sborov, D. [6 ]
Zaugg, B. E. [7 ]
Popat, R. [8 ]
Degli, Esposti S. [9 ,10 ]
Baron, J. [11 ]
Doherty, A. [12 ]
Lewis, E. [13 ]
Opalinska, J. [11 ]
Paka, P. [11 ]
Piontek, T. [11 ]
Gupta, I [11 ]
Farooq, A., V [14 ]
Jakubowiak, A. [14 ]
机构：
[1] Univ Klinkum Carl Gustav, Dresden, Germany
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Emory Univ, Emory Eye Ctr, Atlanta, GA 30322 USA
[4] Univ Maryland, Sch Med, Baltimore, MD USA
[5] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[6] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[7] Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA
[8] Univ Coll London Hosp, NHS Fdn Trust, London, England
[9] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England
[10] UCL Inst Ophthalmol, London, England
[11] GlaxoSmithKline, Providence, RI USA
[12] GlaxoSmithKline, Collegeville, MN USA
[13] GlaxoSmithKline, Res Triangle Pk, NC USA
[14] Univ Chicago, Med Ctr, Chicago, IL USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ep271
引用
收藏
页码：181 / 181
页数：1
相关论文
共 50 条
  • [41] DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma
    Thibaud Prawitz
    Rakesh Popat
    Attaya Suvannasankha
    Grammati Sarri
    Rachel Hughes
    Feng Wang
    Cosmina Hogea
    Shannon Allen Ferrante
    Boris Gorsh
    Jenny Willson
    Venediktos Kapetanakis
    Advances in Therapy, 2021, 38 : 5501 - 5518
  • [42] Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf).
    Terpos, Evangelos
    Badros, Ashraf
    Popat, Rakesh
    Rodriguez-Otero, Paula
    Farooq, Asim
    Jeng, Bennie
    Esposti, Simona Degli
    Lewis, Eric
    Gupta, Ira
    Opalinska, Joanna
    Palumbo, Antonio
    Trudel, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] No Evidence of BCMA Expression Loss or Systemic Immune Impairment after Treatment with the BCMA-Targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Lowther, Daniel E.
    Houseman, E. Andres
    Han, Gang
    Kleanthous, Eleni
    Knoblock, Dawson
    Zhou, Xiangdong
    Banerjee, Shreyan
    Patel, Sagar
    Figueroa, David
    BLOOD, 2022, 140
  • [44] Low-dose belantamab mafodotin (belamaf) in combination with nirogacestat vs belamaf monotherapy in patients with relapsed/refractory multiple myeloma (RRMM): phase I/II DREAMM-5 platform sub-study 3
    Leypoldt, L.
    Callander, N. S.
    Richardson, P. G.
    Hus, M.
    Ribrag, V.
    Lopez, J. M.
    Kim, K.
    Lee, J. H.
    Dimopoulos, M. A.
    Schjesvold, F.
    Facon, T.
    Jo, J. -C.
    Min, C. -K.
    Mielnik, M.
    Cheng, S.
    Smith, L. M.
    Breitbach, C. J.
    Brawley, C.
    Sembhi, H.
    LaMacchia, J.
    Grosicki, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 176 - 177
  • [45] DREAMM-5 platform trial: Belantamab Mafodotin (GSK2857916; belamaf; BLENREP) in combination with five different novel agents in patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Weisel, K.
    Richardson, P. G.
    Trudel, S.
    Callander, N.
    Nooka, A.
    Song, K.
    Uttervall, K.
    Minnema, M. C.
    Rodriguez-Otero, P.
    Struemper, H.
    Yeakey, A.
    de Oca, Montes R.
    Smith, L. M.
    Jackson, N.
    Kaisermann, M.
    Im, E.
    Basile, F. G.
    Ahlers, C. M.
    Holkova, B.
    Gupta, I
    Kremer, B. E.
    Quach, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 204 - 205
  • [46] DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor plus Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma
    Prawitz, Thibaud
    Popat, Rakesh
    Suvannasankha, Attaya
    Sarri, Grammati
    Hughes, Rachel
    Wang, Feng
    Hogea, Cosmina
    Ferrante, Shannon Allen
    Gorsh, Boris
    Willson, Jenny
    Kapetanakis, Venediktos
    ADVANCES IN THERAPY, 2021, 38 (11) : 5501 - 5518
  • [47] Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study
    Hungria, Vania
    Weisel, Katja
    Currie, Brooke
    Perera, Sue
    Sule, Neal
    He, Wei
    Davy, Katherine
    McKeown, Astrid
    Sapra, Sandhya
    Nelsen, Linda
    Li, Mary
    Barale, Sophie
    Boyle, Julia
    McPoyle, Kaytlyn
    Dimopoulos, Meletios Athanasios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S505 - S505
  • [48] Relationship Between Corneal Exam Findings, Best-Corrected Visual Acuity (BCVA), and Ocular Symptoms in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Receiving Belantamab Mafodotin (GSK2857916; Belamaf)
    Terpos, Evangelos
    Badros, Ashraf
    Popat, Rakesh
    Rodriguez-Otero, Paula
    Farooq, Asim
    Jeng, Bennie
    Degli Esposti, Simona
    Lewis, Eric
    Gupta, Ira
    Opalinska, Joanna
    Palumbo, Antonio
    Trudel, Suzanne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S421 - S421
  • [49] Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis
    Quach, Hang
    Gironella, Mercedes
    Lee, Cindy
    Popat, Rakesh
    Cannell, Paul
    Kasinathan, Ravi S.
    Chopra, Bikramjit
    Rogers, Rachel
    Ferron-Brady, Geraldine
    Shafi-Harji, Seema
    Patel, Nashita
    Opalinska, Joanna
    Gupta, Ira
    Augustson, Bradley
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S423 - S424
  • [50] Characterization and Management of Ocular Events in Patients (Pts) Treated With Belantamab Mafodotin (Belamaf) Plus Bortezomib and Dexamethasone (BVd) in the DREAMM-7 Study
    Hungria, Vania T. M.
    Robak, Pawel
    Hus, Marek
    Fu, Chengcheng
    Zherebtsova, Vera
    Ward, Christopher
    Ho, P. Joy
    Hajek, Roman
    Kim, Kihyun
    de lacerda, Marcelo Pitombeira
    Aparecida-Martinez, Gracia
    Dimopoulos, Meletios
    Cerchione, Claudio
    Pirooz, Nick
    McKeown, Astrid
    Rogers, Rachel
    Kazeem, Benga
    Wang, Zhaohui
    Baig, Hena
    Eccersley, Lydia
    Roy-Ghanta, Sumita
    Opalinska, Joanna
    Mateos Manteca, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S262 - S263
12345